A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.

NCT00034489 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: pemetrexed
DRUG: gemcitabine

Sponsor

Eli Lilly and Company